Fibrocell Science Inc. (FCSC)

0.62
NASDAQ : Health Technology
Prev Close 0.64
Day Low/High 0.60 / 0.64
52 Wk Low/High 0.51 / 4.64
Avg Volume 407.10K
Exchange NASDAQ
Shares Outstanding 28.36M
Market Cap 18.09M
EPS -1.30
Div & Yield N.A. (N.A)

Latest News

Fibrocell Reports Third Quarter 2017 Financial Results And Recent Highlights

Fibrocell Reports Third Quarter 2017 Financial Results And Recent Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EST

Fibrocell Reports Second Quarter 2017 Financial Results And Recent Highlights

Fibrocell Reports Second Quarter 2017 Financial Results And Recent Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT

Fibrocell Receives Rare Pediatric Disease Designation From FDA For FCX-013 For Treatment Of Localized Scleroderma

Gene Therapy Candidate under Control of RheoSwitch Therapeutic System® Technology is Potential First-in-Class Treatment for Chronic Disease with High Unmet Need

Fibrocell Reports First Quarter 2017 Financial Results And Recent Operational Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT

Fibrocell And Intrexon Announce Two Oral Presentations At The 20th Annual Meeting Of The American Society Of Gene & Cell Therapy

Highlighting Pre-Clinical Data for Gene Therapy Candidates: FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa and FCX-013 for the Treatment of Linear Scleroderma

Fibrocell Announces One-for-Three Reverse Stock Split

Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on March 13, 2017

Fibrocell Reports 2016 Financial Results And Recent Operational Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EST